London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
SP starting to move now!!
Perhaps this was the leak??
40% since Wednesday
Ah, here we go. It’s waking up now.
About time. This is huge news. The govn clearly likes what it saw in P1.
Bruker is waiting to sell the test and the US market is primed.
The other pro is reusing mass spec machines in hospital labs. They are already there, so less equipment required.
The share price reaction here really does blow my mind sometimes.
The tender explicitly states they are now pivoting to mass population testing.
They are spend 2.5m on a scoping exercise for this, to run BAMs through paces....
We know bams ‘works’ as being used for research already and high sensitive...
It’s through P1 stage so government know that too...
Literally could be like the NCYT PCR contracts in terms of value (coming our way) and literally zero reaction on the sp.
Madness!
@poundcake
Is this us?
See link on bids stats website as posted.
@poundcake
Where was this mentioned??
Thank you
30 seconds per test
1,000 per operator/machine a day... 2k if 24 hour shifts
Cheaper, quicker and hopefully as accurate as pcr
What exactly is the pro for mass spec as opposed to the current process being used by the Government. I am mainly invested for the saliva test and cancer but hadn't really looked into this aspect of Avacta. Like I know Mass Spec allows more test results within a day but by how much more?
*validation
Are there any other Mass spec products going through valdiation?
Remarkable there is no share price response or interest in this...
Govn says it is about to consider using bams in mass testing for the population and zip!
So it looks like clinical validation will come early January when bruker will be able to start flogging the product!
Looks like bams has passed the p1 feasibility study anyway.
Surely Al could give an update on this.
“ The Department wishes to engage with the market in order to share information about potential upcoming opportunities and understand the capacity and capability of the market. ”
2.5m is for the scoping exercise.
Bams roll out in January it looks like.
Event being held next week which is being recorded.... ;)
Only 2.5million. Or is that just to supply consumables and lab space?
Thanks
"NHS Test and Trace: Mass Spectrometry Pilot P2 – P3
Source: OJEU
Published: Fri 20 Nov 2020
Testing for Coronavirus is a crucial part of the government’s response to the pandemic.
research laboratorydhscnhsmass spectrometry pilot p2mass spectrometrynhs testnational covid-19 testing strategymass population testingpublished methods of mass spectrometrynhs test centres
Future contract
pin£2.5M "
https://bidstats.uk/tenders/?q=published+methods+of+mass+spectrometry#739377151-739311716-16
Testing for Coronavirus is a crucial part of the government’s response to the pandemic. The national Covid-19 testing strategy has pivoted toward mass population testing. To achieve this ambition a concerted effort to mobilise a range of viable testing solutions is needed. Following a feasibility study (‘P1’), the initiation of targeted pilot studies are proposed as the next step in mobilising mass spectrometry for Covid-19 testing. This PIN is for a market engagement event to understand the capacity and capability of the market for goods and services that DHSC envisions may be required under the next phases of the pilot (P2 and P3).